Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2008-03-18
2008-03-18
Nickol, Gary B. (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S085100, C424S130100, C424S141100
Reexamination Certificate
active
07344716
ABSTRACT:
The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.
REFERENCES:
patent: 3678158 (1972-07-01), Sussman
patent: 4341867 (1982-07-01), Johansen
patent: 4427649 (1984-01-01), Dingle et al.
patent: 4435506 (1984-03-01), Jackson et al.
patent: 4696816 (1987-09-01), Brown
patent: 5095037 (1992-03-01), Iwamitsu et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5223248 (1993-06-01), McNamara et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5231024 (1993-07-01), Moeller et al.
patent: 5258371 (1993-11-01), Golub et al.
patent: 5270300 (1993-12-01), Hunziker
patent: 5368841 (1994-11-01), Trauner et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5510370 (1996-04-01), Hock
patent: 5656272 (1997-08-01), Le et al.
patent: 5656644 (1997-08-01), Adams et al.
patent: 5728396 (1998-03-01), Peery et al.
patent: 5833984 (1998-11-01), Eibl et al.
patent: 5942499 (1999-08-01), Radomsky
patent: 5965583 (1999-10-01), Beers et al.
patent: 6049026 (2000-04-01), Muschler
patent: 6277969 (2001-08-01), Le et al.
patent: 6284471 (2001-09-01), Le et al.
patent: 6294170 (2001-09-01), Boone et al.
patent: 6340369 (2002-01-01), Ferree
patent: 6352557 (2002-03-01), Ferree
patent: 6419944 (2002-07-01), Tobinick
patent: 6541477 (2003-04-01), Goehring et al.
patent: 6554830 (2003-04-01), Chappius
patent: 6590081 (2003-07-01), Zhang
patent: 6623472 (2003-09-01), Reincke et al.
patent: 6713246 (2004-03-01), Reinecke et al.
patent: 6756215 (2004-06-01), Wolfraim et al.
patent: 2001/0006948 (2001-07-01), Kang et al.
patent: 2001/0016195 (2001-08-01), Tobinick
patent: 2001/0026801 (2001-10-01), Tobinick
patent: 2002/0010471 (2002-01-01), Wironen et al.
patent: 2002/0026244 (2002-02-01), Trieu
patent: 2002/0032155 (2002-03-01), Ferree
patent: 2002/0082697 (2002-06-01), Damien
patent: 2002/0107200 (2002-08-01), Chang et al.
patent: 2002/0169162 (2002-11-01), Smith et al.
patent: 2002/0198599 (2002-12-01), Haldimann
patent: 2003/0007972 (2003-01-01), Tobinick
patent: 2003/0039651 (2003-02-01), Olmarker
patent: 2003/0049256 (2003-03-01), Tobinick
patent: 2003/0069639 (2003-04-01), Sander et al.
patent: 2003/0134792 (2003-07-01), Pike et al.
patent: 2003/0207827 (2003-11-01), Boyle et al.
patent: 2004/0022864 (2004-02-01), Freyman et al.
patent: 2004/0126372 (2004-07-01), Banerjee et al.
patent: 2004/0193274 (2004-09-01), Trieu
patent: 2004/0228853 (2004-11-01), Serhan et al.
patent: 2004/0229786 (2004-11-01), Attawia et al.
patent: 2004/0229878 (2004-11-01), DiMauro et al.
patent: 2005/0025765 (2005-02-01), DiMauro et al.
patent: 2005/0038001 (2005-02-01), Attawia et al.
patent: 2005/0100538 (2005-05-01), Attawia et al.
patent: 2005/0112091 (2005-05-01), DiMauro et al.
patent: 218 868 (1987-04-01), None
patent: 288 088 (1988-10-01), None
patent: 0 438234 (1991-07-01), None
patent: 0 950417 (1999-10-01), None
patent: 1 133995 (1999-10-01), None
patent: 1 153607 (2001-11-01), None
patent: 1 464307 (2004-10-01), None
patent: WO 91/02078 (1991-02-01), None
patent: WO 92/07076 (1992-04-01), None
patent: WO 92/16553 (1992-10-01), None
patent: WO 93/16099 (1993-08-01), None
patent: WO 97/28828 (1997-08-01), None
patent: WO 98/24477 (1998-06-01), None
patent: WO 99/45923 (1999-09-01), None
patent: WO 01/85179 (2001-11-01), None
patent: WO 02/057240 (2002-07-01), None
patent: WO 02/100387 (2002-12-01), None
patent: WO 03/000190 (2003-01-01), None
patent: WO 04/022078 (2004-03-01), None
patent: WO 2005/000283 (2005-01-01), None
patent: WO 2005/110276 (2005-11-01), None
patent: WO 2006/031376 (2006-03-01), None
Tracey et al., Nouv Rev Fr Hematol. 1992; 34 Suppl: S37-42, Abstract only.
LaVan et al (2003, Nature Biotechnology 21:1184-1189.
Marriott et al., J Immunol., 1998 Oct 15;161(8):4236-43.
Olmarker, K. and Rydevik, B., “Selective Inhibition of Tumor Necrosis Factor-α Prevents Nucleus Pulposus-Induced Thrombus Formation, Intraneural Edema, and Reduction of Nerve Conduction Velocity,”Spine, 26(8): 863-869 (2001).
Tobinick, E. and Davoodifar, S., “Perispinal TNF-alpha Inhibition for Discogenic Pain,”Swiss Med. Wkly, 133:170-177 (2003).
Karppinen, J. et al., “Tumor Necrosis Factor-α Monoclonal Antibody, Infliximab, Used to Manage Severe Sciatica,”Spine, 28(8):750-754 (2003).
Alini, M. et al., “A Biological Approach to Treating Disc Degeneration: Not for Today, but Maybe for Tomorrow,”Eur. Spine J., 11(Suppl 2):S215-S220 (2002).
Brown, K. et al., “Gelatin/Chondroitin 6-Sulfate Microspheres for the Delivery of Therapeutic Proteins to the Joint,”Arthritis. & Rheum., 42(12):2185-2195 (1998).
Kozbor, D. et al., “The Production of Monoclonal Antibodies form Human Lymphocytes,”Immunol. Today, 4(3):72-79 (1983).
Burke, J.G. et al., “Intervertebral Discs Which Cause Low Back Pain Secrete High Levels of Proinflammatory Mediators,”J. Bone Joint Surg. [Br], 84-B, 196-201 (2002).
Zhang, C. et al., “Mitogen-activated Protein (MAP) Kinase Regulates Production of Tumor Necrosis Factor-α and Release of Arachidonic Acid in Mast Cells,”J. Biol. Chem., 272(20): 13397-13402 (1997).
Pargellis, C. et al., “Inhibition of p38 MAP Kinase by Utilizing a Novel Allosteric Binding Site,”Nature Structural Biology, 9(4): 268-272 (2002).
Chae, H.J. et al., “The p38 Mitogen-activated Protein Kinase Pathway Regulates Interleukin-6 Synthesis in Response to Tumor Necrosis Factor in Osteoblasts,”Bone, 28(1): 45-53 (2001).
Aoki, Y. et al., “Local Application of Disc-Related Cytokines on Spinal Nerve Roots,”Spine, 27(15): 1614-1617 (2002).
Takegami, K. et al., “Osteogenic Protein-1 Enhances Matrix Replenishment by Intervertebral Disc Cells Previously Exposed to Interleukin-1,”Spine, 27(12):1318-1325 (2002).
Diwan, A. et al., “Current Concepts in Intervertebral Disk Restoration,”Tissue Engineering in Orthopedic Surgery, 31(3):453-464 (2000).
Ariga, K. et al., “Mechanical Stress-Induced Apoptosis of Endplate Chondrocytes in Organ-Cultured Mouse Intervertebral Discs,”Spine, 28(14):1528-1533 (2003).
Möller, A. et al., “Monoclonal Antibodies to Human Tumor Necrosis Factor α: In Vitro and In Vivo Application,”Cytokine, 2(3):162-169 (1990).
Liang, C.-M. et al., “Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin,”Biochem. Biophys. Res. Comm.,137:847-854 (1986).
Meager, A. et al., “Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumor Necrosis Factor (rTNF),”Hybridoma, 6(3):305-311 (1987).
Fendly, B. et al., “Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor,”Hybridoma, 6(4):359-370 (1987).
Bringman, T.S. et al., “Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Application for Affinity Purification, Immunoassays, and as Structural Probes,”Hybridoma, 6(5):489-507 (1987).
Hirai, M. et al., “Production and Characterization of Monoclonal Antibodies to Human Tumor Necrosis Factor,”J. Immunol. Meth., 96:57-62 (1987).
Schall, T. et al., “Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor,”Cell, 61:361-370 (1990).
Loetscher, H. et al., “Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor,”Cell, 61:351-359 (1990).
Corcoran, A. et al., “Characterization of Ligand Binding by the Human p55 Tumour-Necrosis-Factor Receptor,”Eur. J. Biochem., 223:831-840 (1994).
Engelmann, H. et al., “Two Tumor Necrosis Factor-Binding Proteins Purified From Human Urine,”J. Biol. Chem., 265(3):1531-1536 (1990).
Lesslauer, W. et al., “Recombinant Soluble Tumor Necrosis Factor Receptor Proteins Protect Mice from Lipopolysaccharide-Induced Lethality,”Eur. J
Attawia Mohamed
DiMauro Thomas M.
Serhan Hassan
DePuy Spine, Inc.
Hamilton Brook Smith & Reynolds P.C.
Nickol Gary B.
Woodward Cherie
LandOfFree
Transdiscal administration of specific inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transdiscal administration of specific inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transdiscal administration of specific inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2790055